Piper plays down significance of Tesla Autopilot case in Florida
Therapeutic Solutions International, Inc. (OTC Markets:TSOI), a micro-cap company with a market capitalization of $1.54 million, has announced a loyalty dividend for its shareholders, a move that underscores the company’s commitment to rewarding its investors. According to InvestingPro data, while the company’s stock has shown significant volatility with a 50% gain year-to-date, it faces challenges with cash management. The dividend will be distributed in shares of its subsidiary Breathe Biologics, Inc. (BRTH), a Delaware stock corporation.
Shareholders of Therapeutic Solutions as of the market close on March 03, 2025, will be eligible to receive the dividend. For every share of TSOI common stock held, shareholders will receive 0.001293129082553 shares of BRTH. The company has set a conversion rate for the dividend distribution, which amounts to approximately 0.1293% of a BRTH share per TSOI share owned. This move comes as the stock has experienced a challenging period, with InvestingPro analysis showing a 60% decline over the past six months.
The decision for this one-time dividend was made by the Board of Directors and the holders of Preferred A Stock, who together represent a majority of voting shareholders. This action was taken in accordance with Nevada Revised Statutes Section NRS 78.215.
Therapeutic Solutions currently owns 86.53% of BRTH common stock, which totals 22,500,000 shares. Out of this, 7,500,000 shares will be allocated for the loyalty dividend to TSOI shareholders. The offer for this dividend will remain open for 60 days, starting from the Dividend Offer Date and ending on May 3, 2025.
Shareholders who wish to receive the dividend must submit a form provided by the company along with a statement from their brokerage account verifying the ownership of TSOI shares on the eligibility date. Upon completion of the required documentation, shareholders will receive a Book Entry Statement reflecting their new holdings in BRTH.
This strategic move by Therapeutic Solutions International aims to enhance shareholder value and demonstrate the company’s confidence in its subsidiary’s potential. The information regarding this dividend is based on a press release statement filed with the SEC.
In other recent news, Therapeutic Solutions International has declared a one-time loyalty dividend for its shareholders. This dividend involves shares in its subsidiary, Breathe Biologics, with a conversion rate of 0.001293129082553 shares of BRTH for each share of Therapeutic Solutions held. Shareholders eligible for this dividend are those holding shares as of March 3, 2025, and the offer will remain open until May 3, 2025. Additionally, the company has amended its corporate charter to increase its authorized shares from 6.5 billion to 9 billion. This amendment was made through a nonunanimous majority written consent of stockholders. The increase in authorized shares could be used for various corporate purposes, although specific reasons were not disclosed. Board members Timothy G. Dixon and Thomas E. Ichim, who hold Series A Preferred stock, consented in favor of the amendment. These recent developments reflect the company’s strategic decisions to reward shareholders and potentially support future corporate activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.